Marco Lisicki

Marco Lisicki

Auto-generated profile, based on publicly available information

Marco Lisicki

Mercedes and Martín Ferreyra Institute for Medical Research

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2019 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
EGElena Gross
Elena Gross
MLMarco Lisicki
Marco Lisicki
DFDirk Fischer
Dirk Fischer
PSPeter S. Sándor
Peter S. Sándor
JSJean Schoenen
Jean Schoenen

13 July 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
NVNicolas Vandenbussche
Nicolas Vandenbussche
DLDomenico Laterza
Domenico Laterza
MLMarco Lisicki
Marco Lisicki
JLJoseph Lloyd
Joseph Lloyd
CLChiara Lupi
Chiara Lupi
ZKZaza Katsarava
Zaza Katsarava
Medication overuse in primary headache disorders is a worldwide phenomenon and has a role in the chronification of headache disorders. The burden of disease on individuals and societies is significant due to high costs and comorbidities. In the Third Edition of the International Classification of Headache Disorders, medication-overuse headache is recognized as a separate secondary entity next to mostly primary headache disorders, although many clinicians see the disease as a sole complication of primary headache disorders. In this review, we explore the historical background of medication-overuse headache, its epidemiology, phenomenology, pathophysiology and treatment options. The review explores relevant unanswered questions and summarizes the current debates in medication-overuse headache.

11 September 2024 in Cephalalgia
Verified
Journal Article
Open access
FPFrancesca Puledda
Francesca Puledda
SSSimona Sacco
Simona Sacco
HDHans-Christoph Diener
Hans-Christoph Diener
MAMessoud Ashina
Messoud Ashina
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
CTCristina Tassorelli
Cristina Tassorelli

29 April 2019 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
Gianluca CoppolaGianluca Coppola
Gianluca Coppola
Cherubino Di LorenzoCherubino Di Lorenzo
Cherubino Di Lorenzo
VPVincenzo Parisi
Vincenzo Parisi
MLMarco Lisicki
Marco Lisicki
MSMariano Serrao
Mariano Serrao
FPFrancesco Pierelli
Francesco Pierelli
The purpose of this review is to provide a comprehensive overview of the findings of clinical electrophysiology studies aimed to investigate changes in information processing of migraine with aura patients. Abnormalities in alpha rhythm power and symmetry, the presence of slowing, and increased information flow in a wide range of frequency bands often characterize the spontaneous EEG activity of MA. Higher grand-average cortical response amplitudes, an increased interhemispheric response asymmetry, and lack of amplitude habituation were less consistently demonstrated in response to any kind of sensory stimulation in MA patients. Studies with single-pulse and repetitive transcranial magnetic stimulation (TMS) have reported abnormal cortical responsivity manifesting as greater motor evoked potential (MEP) amplitude, lower threshold for phosphenes production, and paradoxical effects in response to both depressing or enhancing repetitive TMS methodologies. Studies of the trigeminal system in MA are sparse and the few available showed lack of blink reflex habituation and abnormal findings on SFEMG reflecting subclinical, probably inherited, dysfunctions of neuromuscular transmission. The limited studies that were able to investigate patients during the aura revealed suppression of evoked potentials, desynchronization in extrastriate areas and in the temporal lobe, and large variations in direct current potentials with magnetoelectroencephalography. Contrary to what has been observed in the most common forms of migraine, patients with familial hemiplegic migraine show greater habituation in response to visual and trigeminal stimuli, as well as a higher motor threshold and a lower MEP amplitude than healthy subjects. Since most of the electrophysiological abnormalities mentioned above were more frequently present and had a greater amplitude in migraine with aura than in migraine without aura, neurophysiological techniques have been shown to be of great help in the search for the pathophysiological basis of migraine aura.

14 February 2023 in Cephalalgia
Verified
Journal Article
Open access
FPFrancesca Puledda
Francesca Puledda
SYSamaira Younis
Samaira Younis
EHEva-Maria Huessler
Eva-Maria Huessler
Faraidoon HaghdoostFaraidoon Haghdoost
Faraidoon Haghdoost
MLMarco Lisicki
Marco Lisicki
CTCristina Tassorelli
Cristina Tassorelli
Background: We performed a random-effects network meta-analysis to study the efficacy and safety of newly developed drugs for the acute treatment of migraine attacks. Methods: MEDLINE via PubMed, Embase and The Cochrane Register of Controlled Trials were searched from inception to 11 February 2022. Phase 3 randomized controlled trials examining all formulations of lasmiditan, rimegepant and ubrogepant for the acute treatment of adults with migraine, were included. Data were extracted following the PRISMA guidelines. Results: Seven studies (SAMURAI, SPARTAN, CENTURION, Study 302, Study 303, ACHIEVE I and II) involving n = 12,859 patients were included. All treatments were superior in efficacy to placebo. Lasmiditan 200 mg showed the highest two-hour pain freedom, while two-hour freedom from most bothersome symptom was equally achieved by the higher doses of lasmiditan (100 and 200 mg), rimegepant and the higher doses of ubrogepant (50 and 100 mg). The odds of treatment-emergent adverse events were greatest with all doses of lasmiditan. Conclusion: Lasmiditan 200 mg was the most effective intervention in the treatment of migraine attacks, although it was associated with high degrees of dizziness, nausea and somnolence. Rimegepant showed slightly lower, but similar efficacy rates to lasmiditan. Ubrogepant had overall the best tolerability profile. These conclusions are limited by the absence of head-to-head comparisons, limitations of individual trials and of the meta-analysis methodology itself. PROSPERO trial registration: CRD42022308224

5 July 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
MLMarco Lisicki
Marco Lisicki
KDKevin D’oStilio
Kevin D’oStilio
Gianluca CoppolaGianluca Coppola
Gianluca Coppola
FSFelix Scholtes
Felix Scholtes
ANAlain Maertens de Noordhout
Alain Maertens de Noordhout
DMDelphine Magis
Delphine Magis
Migraine attacks might be triggered by a disruption of cerebral homeostasis. During the interictal period migraine patients are characterized by abnormal sensory information processing, but this functional abnormality may not be sufficient to disrupt the physiological equilibrium of the cortex unless it is accompanied by additional pathological mechanisms, like a reduction in energetic reserves. The aim of this study was to compare resting cerebral glucose uptake (using positron emission tomography (18fluorodeoxyglucose-PET)), and visual cortex activation (using visual evoked potentials (VEP)), between episodic migraine without aura patients in the interictal period and healthy volunteers. Twenty episodic migraine without aura patients and twenty healthy volunteers were studied. 18FDG-PET and VEP recordings were performed on separate days. The overall glucose uptake in the visual cortex-to-VEP response ratio was calculated and compared between the groups. Additionally, PET scan comparisons adding area under the VEP curve as a covariate were performed. For case-wise analysis, eigenvalues from a specific region exhibiting significantly different FDG-PET signal in the visual cortex were extracted. Standardized glucose uptake values from this region and VEP values from each subject were then coupled and compared between the groups. The mean area under the curve of VEP was greater in migraine patients compared to healthy controls. In the same line, patients had an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex. Statistical parametric mapping analysis revealed that cortical FDG-PET signal in relation to VEP area under the curve was significantly reduced in migraineurs in a cluster extending throughout the left visual cortex, from Brodmann’s areas 19 and 18 to area 7. Within this region, case-wise analyses showed that a visual neuronal activation exceeding glucose uptake was present in 90% of migraine patients, but in only 15% of healthy volunteers. This study identifies an area of increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients between attacks. Such observation supports the concept that an activity-induced rupture of cerebral metabolic homeostasis may be a cornerstone of migraine pathophysiology. This article has been selected as the winner of the 2018 Enrico Greppi Award. The Enrico Greppi Award is made to an unpublished paper dealing with clinical, epidemiological, genetic, pathophysiological or therapeutic aspects of headache. Italian Society for the Study of Headaches (SISC) sponsors this award, and the award is supported through an educational grant from Teva Neuroscience. This article did not undergo the standard peer review process for The Journal of Headache and Pain. The members of the 2018 Enrico Greppi Award Selection Committee were: Francesco Pierelli, Paolo Martelletti, Lyn Griffiths, Simona Sacco, Andreas Straube and Cenk Ayata.